Management of Factor Xa–Associated Life-Threatening Hemorrhage

In an industry-sponsored study, investigators reviewed charts at five centers, to describe current management practices for patients with factor Xa inhibitor–associated life-threating hemorrhage.

Of 56 patients studied, roughly half had gastrointestinal hemorrhages and one third had intracranial hemorrhages. Various coagulation factor or plasma products were administered to 43% of patients, and no attempt at reversal of anticoagulation was made for the remainder. At 30 days, mortality was 21%, and 41% of patients had been re-anticoagulated.